Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

UToledo Researcher Tackles Drug Resistance in Aggressive Breast Cancer

July 24, 2026

[University of Toledo] A University of Toledo researcher has received a grant from the National Cancer Institute of the National Institutes of Health to investigate a new strategy for overcoming one of the most stubborn obstacles in treating TNBC: resistance to chemotherapy.

Spatial Ecology of Breast Cancer Reveals Co-Evolution of Proliferative and Dormant Niches

July 24, 2026

[Genome Medicine] Investigators leveraged single-cell and spatially profiled primary breast tumours to quantify G0 arrest and proliferation decisions in cancer cells, revealing molecular and spatial features associated with proliferation-G0 dynamics.

Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer

July 24, 2026

[Advanced Healthcare Materials] Scientists developed a carrier-free co-assembled nanoplatform, designated as IR@PF-M NPs, to enhance photothermal-immunotherapy against TNBC by reprogramming methionine metabolism.

Restoring the CD226 in CD8T Cells Overcomes TIGIT-Refractory Immunity in HER2 Breast Cancer

July 24, 2026

[Cell Death & Disease] Researchers showed that restoring CD226-mediated co-stimulation overcomes TIGIT-refractory immunity and sensitizes HER2+ tumors to anti-HER2 therapy, positioning CD226 as both a pharmacodynamic driver and a clinically actionable biomarker for patient selection and response monitoring.

Targeting PFKL with S-Benzylisothiourea Imidazolium Salt Derivatives to Suppress Glycolysis and Treat Breast Cancer

July 24, 2026

[Journal of Medicinal Chemistry] Investigators synthesized a series of S-benzylisothiourea imidazolium salt derivatives and identified compound 10w, which potently inhibited breast cancer cell proliferation, suppressed glycolysis, and induced apoptosis.

CEACAM1 Participation in Breast Cancer Progression

July 24, 2026

[Molecular Oncology] Scientists investigated the functional roles of CEACAM1 isoforms and their potential diagnostic significance in invasive breast cancer tissues, as well as their association with the proliferative index of carcinoma cells.

Unveiling Isoleucyl-tRNA Synthetase 2 As a Novel Driver of Breast Cancer via β-Catenin Pathway Activation

July 24, 2026

[Journal of Cell Communication and Signaling] The authors investigated whether Isoleucyl-tRNA synthetase 2 (IARS2) affects the development of breast cancer and whether β-catenin signaling is involved.

The Role of Ferroptosis in the Pathogenesis and Treatment of Breast Cancer

July 24, 2026

[Journal of Translational Medicine] Ferroptosis represents a pivotal mechanism in the pathogenesis and therapeutic response of breast cancer. Targeting ferroptosis pathways offers a promising strategy to enhance treatment sensitivity, overcome drug resistance, and improve patient prognosis.

Core Genes Drive Treatment Resistance in Triple-Negative Breast Cancer: Characteristics, Mechanisms, Intervention Strategies

July 24, 2026

[Biochemical Pharmacology] Scientists summarize the primary resistance genes associated with treatment failure in TNBC, along with their fundamental characteristics and mechanisms of action

Dissection of Mammary Cell Landscape in Ruminal Dysbiosis-Induced Mastitis by Single-Cell RNA Sequencing

July 9, 2026

[NPJ Biofilms and Microbiomes] Researchers profiled mammary single-cell transcriptomes in goats with ruminal dysbiosis-induced mastitis, complemented by ruminal metagenomic and untargeted metabolomic analyses of rumen fluid and serum.

Recipients of OnkPat’s 2026 Blue Sky Grant Announced

July 9, 2026

[Karolinska Institutet] The Department of Oncology‑Pathology at Karolinska Institutet has announced the recipients of the 2026 Blue Sky Grant, an internal funding call aimed at supporting innovative, cross‑disciplinary research led by early‑career researchers.

Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer

July 9, 2026

[DFCI] The US FDA has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the Phase III PATINA study led by Dr. Otto Metzger, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.